Par Pharmaceutical Receives Approval For Nateglinide Tablets
Par Pharmaceutical has received final approval from the FDA for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis’ Starlix. The company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.